Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients

Author:

Jan Chia-Ing,Yu Cheng-Chia,Hung Mien-Chie,Harn Horng-Jyr,Nieh Shin,Lee Herng-Sheng,Lou Mary Ann,Wu Yi-Chen,Chen Chi-Yuan,Huang Chi-Yang,Chen Fei-Na,Lo Jeng-Fan

Funder

National Science Council

Taipei Veterans General Hospital

National Yang-Ming University (Ministry of Education

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference38 articles.

1. Effect of screening and adjuvant therapy on mortality from breast cancer;Berry;N Engl J Med,2005

2. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

3. Grand challenges in global health and the practical prevention program? Asian focus on cancer prevention in females of the developing world;Moore;Asian Pac J Cancer Prev,2003

4. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis;Shen;Cancer Epidemiol Biomarkers Prev,2005

5. HER2 status and benefit from adjuvant trastuzumab in breast cancer;Paik;N Engl J Med,2008

Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3